C
Corbus Pharmaceuticals Holdings D
D
CRBP
7.60000
USD
-0.16
(-2.03%)
مغلق
حجم التداول
1,913
الربح لكل سهم
-6
العائد الربحي
-
P/E
-2
حجم السوق
92,999,429
الأخبار المقالات
العنوان: Corbus Pharmaceuticals Holdings
القطاع: Healthcare
الصناعة: Biotechnology
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.